{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:15:09Z","timestamp":1793798109759,"version":"4.6.1"},"reference-count":103,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The gut microbiome has emerged as a critical determinant of immune-checkpoint inhibitor (ICI) efficacy. A narrative review of 95 clinical studies (2015\u20132025) shows that patients with greater gut microbial diversity and relative enrichment of commensals such as Akkermansia, Ruminococcus, and other short-chain fatty acid producers experience longer progression-free and overall survival, particularly in melanoma and non-small-cell lung cancer. Broad-spectrum antibiotics given within 30 days of ICI initiation and over-the-counter mixed probiotics consistently correlate with poorer outcomes. Early phase I\/II trials of responder-derived fecal microbiota transplantation in ICI-refractory melanoma achieved objective response rates of 20\u201340%, while pilot high-fiber or plant-forward dietary interventions improved immunologic surrogates such as CD8+ tumor infiltration. Machine-learning classifiers that integrate 16S or metagenomic profiles predict ICI response with an area under the ROC curve of 0.83\u20130.92. Methodological heterogeneity across sampling, sequencing, and clinical endpoints remains a barrier, underscoring the need for standardization and larger, well-powered trials.<\/jats:p>","DOI":"10.3390\/medicina61091595","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:55:37Z","timestamp":1756983337000},"page":"1595","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review"],"prefix":"10.3390","volume":"61","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[{"name":"Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, BG, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-2018","authenticated-orcid":false,"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[{"name":"Oncology Unit, Casa di Cura Igea, 20129 Milano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, BG, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-1218","authenticated-orcid":false,"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione Poliambulanza, 25124 Brescia, BS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0941-8547","authenticated-orcid":false,"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[{"name":"Oncology Unit, ASST Crema, 26013 Crema, CR, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zuo, T., and Ng, S.C. (2018). The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02247"},{"key":"ref_6","first-page":"18","article-title":"Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma","volume":"5","author":"Frankel","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1462-2920.13589","article-title":"Formation of propionate and butyrate by the human colonic microbiota","volume":"19","author":"Louis","year":"2017","journal-title":"Environ. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","article-title":"The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: A systematic review and meta-analysis of observational studies","volume":"69","author":"Wilson","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.adh7954","article-title":"Vitamin D regulates microbiome-dependent cancer immunity","volume":"384","author":"Giampazolias","year":"2024","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.medj.2024.07.002","article-title":"Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer","volume":"5","author":"Yang","year":"2024","journal-title":"Med"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2019.37.15_suppl.101","article-title":"The gut microbiome (GM) and probiotics influence response to immune checkpoint blockade (ICB) in melanoma","volume":"37","author":"Choueiri","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: Results of a phase 1b, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2019.06.002","article-title":"Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells","volume":"51","author":"Bachem","year":"2019","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1002\/mco2.417","article-title":"Microbiota in cancer: Molecular mechanisms and therapeutic interventions","volume":"4","author":"Chen","year":"2023","journal-title":"MedComm"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Qi, Y., Duan, G., Wei, D., Zhao, C., and Ma, Y. (2022). The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?. Molecules, 27.","DOI":"10.3390\/molecules27165292"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.cell.2021.06.019","article-title":"Gut-microbiota-targeted diets modulate human immune status","volume":"184","author":"Wastyk","year":"2021","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/cmi.12308","article-title":"Defining dysbiosis and its influence on host immunity and disease","volume":"16","author":"Petersen","year":"2014","journal-title":"Cell Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-025-02359-x","article-title":"Integrative multi-omics analysis reveals the LncRNA 60967.1-PLCD4-ATRA axis as a key regulator of colorectal cancer progression and immune response","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10609","DOI":"10.1038\/s41467-024-54565-8","article-title":"Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer","volume":"15","author":"Rosario","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2430087","DOI":"10.1080\/21645515.2024.2430087","article-title":"Unraveling the role of gut microbiome in predicting adverse events in neoadjuvant therapy for rectal cancer","volume":"20","author":"Ma","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/1878-0261.13760","article-title":"Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer","volume":"19","author":"Ullern","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27791","DOI":"10.1038\/s41598-024-79339-6","article-title":"Dietary pattern and the corresponding gut microbiome in response to immunotherapy in Thai patients with advanced non-small cell lung cancer (NSCLC)","volume":"14","author":"Sitthideatphaiboon","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1038\/s41467-024-49842-5","article-title":"A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-024-07395-7","article-title":"Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer","volume":"208","author":"Nakamoto","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1158\/2767-9764.CRC-23-0479","article-title":"Role of gut microbiome in neoadjuvant chemotherapy response in urothelial carcinoma: A multi-institutional prospective cohort evaluation","volume":"4","author":"Bukavina","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","article-title":"Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: Impact of antibiotic preconditioning","volume":"14","author":"Glitza","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: A phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","article-title":"Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor","volume":"32","author":"Kim","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: The phase 2 NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: Phase 1 trial interim results","volume":"29","author":"Ferguson","year":"2023","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomized phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41591-024-02823-z","article-title":"A gut microbial signature for combination immune checkpoint blockade across cancer types","volume":"30","author":"Gunjur","year":"2024","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/atm-20-6427","article-title":"The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer","volume":"9","author":"Naqash","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_48","first-page":"e00134","article-title":"Fecal microbiota transplantation alleviates immune checkpoint inhibitor-induced colitis","volume":"11","author":"Chang","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_49","first-page":"3891","article-title":"Gut microbiome composition modulates the antitumor effect of PD-1 blockade in murine models","volume":"23","author":"Wang","year":"2018","journal-title":"Cell. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti\u2013PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell."},{"key":"ref_54","first-page":"616","article-title":"Relating the gut microbiome and outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors","volume":"111","author":"Peters","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","article-title":"Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial","volume":"42","author":"Davar","year":"2024","journal-title":"Cancer Cell."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wang, Y., Huang, S., Feng, X., Xu, W., Luo, R., Zhu, Z., Zeng, Q., and He, Z. (2023). Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1145128"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non\u2013small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1568812","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The diversity of gut microbiome is associated with favorable responses to anti\u2013PD-1 immunotherapy in Chinese patients with NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/2326-6066.CIR-19-1014","article-title":"The gut microbiome is associated with clinical response to anti\u2013PD-1\/PD-L1 immunotherapy in gastrointestinal cancer","volume":"8","author":"Peng","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_63","first-page":"651","article-title":"Antibiotics are associated with attenuated efficacy of immune checkpoint blockers in patients with advanced renal cell and non\u2013small-cell lung cancer","volume":"30","author":"Coutzac","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","article-title":"The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced NSCLC","volume":"8","author":"Hakozaki","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e178897","DOI":"10.1172\/JCI184321","article-title":"The gut microbiome and cancer response to immune checkpoint inhibitors","volume":"135","author":"Gazzaniga","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_66","first-page":"264","article-title":"Cross-talk between microbiota and immune fitness to steer and control response to anti\u2013PD-1\/PD-L1 treatment","volume":"38","author":"Botticelli","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00284-025-04408-6","article-title":"Non-small Cell Lung Cancer, Immunotherapy and the Influence of Gut Microbiome","volume":"82","author":"Raziq","year":"2025","journal-title":"Curr. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor\u2013associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_69","first-page":"3195","article-title":"Antibiotic Use Does Not Appear to Influence Response to Nivolumab","volume":"37","author":"Kaderbhai","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/s41598-025-89406-1","article-title":"Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients","volume":"15","author":"Grenda","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"217123","DOI":"10.1016\/j.canlet.2024.217123","article-title":"The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect","volume":"598","author":"Xia","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Petrelli, F., Iaculli, A., Signorelli, D., Ghidini, A., Dottorini, L., Perego, G., Cabiddu, M., Borgonovo, K., Parati, M.C., and Ghilardi, M. (2020). Survival of patients treated with antibiotics and immunotherapy for cancer: A systematic review and meta-analysis. J. Clin. Med., 9.","DOI":"10.20944\/preprints202003.0425.v1"},{"key":"ref_73","first-page":"1900","article-title":"Association of short-chain fatty acids in the gut with response to nivolumab in advanced non\u2013small cell lung cancer","volume":"9","author":"Nomura","year":"2020","journal-title":"Transl. Lung. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41467-019-09525-y","article-title":"Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5\u2013\/\u2013 mice","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Pitt","year":"2015","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cell.2018.08.047","article-title":"Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT","volume":"174","author":"Suez","year":"2018","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri.2016.36","article-title":"Development and maintenance of intestinal regulatory T cells","volume":"16","author":"Tanoue","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"eaaw4361","DOI":"10.1126\/science.aaw4361","article-title":"Laboratory mice born to wild mice have natural microbiota and model human immune responses","volume":"365","author":"Rosshart","year":"2019","journal-title":"Science"},{"key":"ref_84","first-page":"844","article-title":"Fecal microbiota transplantation for refractory melanoma patients: Mechanisms and predictive biomarkers","volume":"29","author":"Baruch","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ma, W., Mao, Q., Xia, W., Dong, G., Yu, C., and Jiang, F. (2019). Gut microbiota shapes the efficiency of cancer therapy. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01050"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liu, W., Wang, Y., Luo, J., Liu, M., and Luo, Z. (2021). Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.586760"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2020-321153","article-title":"The role of gut microbiota in cancer treatment: Friend or foe?","volume":"69","author":"Cheng","year":"2020","journal-title":"Gut"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1900623","article-title":"Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation","volume":"382","author":"Peled","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Oh, B., Boyle, F., Pavlakis, N., Clarke, S., Eade, T., Hruby, G., Lamoury, G., Carroll, S., Morgia, M., and Kneebone, A. (2021). The gut microbiome and cancer immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13194824"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","article-title":"Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment","volume":"14","author":"Kostic","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1470-2045(18)30952-5","article-title":"Modulating the microbiome to improve therapeutic response in cancer","volume":"20","author":"McQuade","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41575-022-00605-x","article-title":"The gut microbiome as a modulator of healthy ageing","volume":"19","author":"Ghosh","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The promises and challenges of tumor mutation burden as an immunotherapy biomarker: A perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Zitvogel","year":"2021","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eabo2003","DOI":"10.1126\/sciimmunol.abo2003","article-title":"Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity","volume":"8","author":"Choi","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-0043-1760864","article-title":"The Influence of the Microbiome on Metastatic Colorectal Cancer","volume":"36","author":"Cass","year":"2023","journal-title":"Clin. Colon Rectal Surg."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Xu, H., Cao, C., Ren, Y., Weng, S., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., and Ren, J. (2022). Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.949490"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"100813","DOI":"10.1016\/j.neo.2022.100813","article-title":"Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)","volume":"31","author":"Michikawa","year":"2022","journal-title":"Neoplasia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: Mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Silva, M., Brunner, V., and Tschurtschenthaler, M. (2021). Microbiota and Colorectal Cancer: From Gut to Bedside. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.760280"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.iotech.2020.05.001","article-title":"Intervention strategies for microbial therapeutics in cancer immunotherapy","volume":"6","author":"Gopalakrishnan","year":"2020","journal-title":"Immunooncol. Technol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1595\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:23Z","timestamp":1760035163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":103,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091595"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091595","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}